Novartis DM1 drug fails late-stage trial, clouding development outlook

2 outlets ·Stocks

0 left · 1 center · 0 right

How each outlet headlined it

• Investing.com Stocks

  Novartis DM1 drug fails late-stage trial, clouding development outlook
  
• Bloomberg center

  Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, the third clinical-trial setback in a week. The medicine was the centerpiece of Novartis’s $12 billion takeover of Avidity Biosciences and raises questions about the drugmaker’s growth prospects. Fabienne Kinzelmann reports on Bloomberg Television. (Source: Bloomberg)